Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
How do you approach treatment selection in patients with rheumatoid arthritis and severe COPD?
Related Questions
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
Do you use the peri-operative management of biologics and DMARDs guidelines, which were mainly based on total hip and knee replacement surgeries, for all peri-operative surgical management?
What is the maximum dose of leucovorin that you use with methotrexate?
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
Would you re-challenge a patient with Rituximab who responded well in terms of their RA but developed symptomatic tachycardia after their first infusion?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
How would you manage a patient with RA with newly diagnosed T-LGLL who was previously treated with Enbrel and is now flaring off Enbrel while on low dose methotrexate?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
How do you approach monitoring when using combination JAK inhibitors and methotrexate in RA?
How do you approach treatment of early onset RA with minimal peripheral disease and aggressive cervical atlantoaxial involvement?
